Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297739 | 0.87 | PTPN2 (0.46) | PTPN2PTPN1PTPN6HPGDEPHX2 | |
| SCHEMBL6505355 | 0.87 | PTPN2 (0.46) | PTPN2PTPN1PTPN6HPGDEPHX2 | |
| SCHEMBL1580316 | 0.82 | HPGD (0.54) | PTPN2PTPN1PTPN6HPGDEPHX2 | |
| SCHEMBL12440443 | 0.79 | HTT (0.53) | PTPN2PTPN1PTPN6HPGDEPHX2 | |
| SCHEMBL413795 | 0.78 | HPGD (0.55) | PTPN2PTPN1PTPN6HPGDEPHX2 | |
| SCHEMBL18768415 | 0.77 | HPGD (0.57) | PTPN2PTPN1PTPN6HPGDEPHX2 | |
| SCHEMBL9938875 | 0.76 | HPGD (0.56) | PTPN2PTPN1PTPN6HPGDRECQL | |
| SCHEMBL1279287 | 0.76 | GPR119 (0.44) | HPGDRECQLHTTKMT2AMEN1 | |
| SCHEMBL1279822 | 0.76 | GPR119 (0.44) | HPGDRECQLHTTKMT2AMEN1 | |
| SCHEMBL1279825 | 0.76 | GPR119 (0.44) | HPGDRECQLHTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| EP-2019837-B1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-03-23 | — | — | EP | disclosed |
| WO-2007140117-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | PTPN2 2313/4885PTPN1 2649/4885PTPN6 3477/4885 |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | PTPN2 2322/4885PTPN1 2645/4885PTPN6 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.